Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Lilly's Prozac (fluoxetine)

  • News

Executive Summary

The serotonin uptake inhibitor is "approvable" for treating depression, the company announces Sept. 11. Lilly also plans to seek a weight loss claim; Prozac has been studied in over 1,000 patients as an anti-obesity agent. FDA's Psychopharmacologic Drugs Advisory committee reviewed the drug in October 1985. Prozac is currently being marketed in Belgium and South Africa for depression, and has been approved for marketing in Italy, where it is awaiting pricing approval.

Table

View full table

Tags:
Latest Headlines

Experts Urge Action On Regulatory Science Collaboration In Korea

Cancer Trials: FDA Wants Lower Performance Status Eligibility But Primary Analysis Exclusion OK

US FDA's Califf Defends Agency Work On Marijuana Rescheduling, Animal Testing

Overall Survival Is Not A Required Primary Endpoint In All Cancer Trials, US FDA Says

See All
UsernamePublicRestriction

Register

PS012479

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By